Skip to Content

NUMETA G13%E PRETERM

Active substance(s): ALANINE / ARGININE / ASPARTIC ACID / CALCIUM CHLORIDE DIHYDRATE / CYSTEINE / GLUCOSE MONOHYDRATE / GLUTAMIC ACID / GLYCINE / HISTIDINE / ISOLEUCINE / LEUCINE / LYSINE MONOHYDRATE / MAGNESIUM ACETATE / METHIONINE / OLIVE OIL REFINED / ORNITHINE HYDROCHLORIDE / PHENYLALANI

View full screen / Print PDF » Download PDF ⇩
Transcript
b

Package leaflet: Information for the user
Numeta G13%E Preterm emulsion for infusion
Read all of this leaflet carefully before you start using this medicine because it contains important
information for you.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your child’s doctor, pharmacist, or nurse.
• If your child gets any side effects, talk to your child’s doctor or nurse. This includes any possible
side effects not listed in this leaflet. See section 4.
The medicine is called Numeta G13%E Preterm emulsion for infusion but will be referred to as Numeta
through the remainder of this leaflet.

What is in this leaflet:
1.
2.
3.
4.
5.
6.

What Numeta is and what it is used for
What you need to know before your child is given Numeta
How Numeta is given
Possible side effects
How to store Numeta
Contents of the pack and other information

1. What Numeta is and what it is used for
Numeta G13E is a specialised nutrition emulsion designed for preterm newborns. It is given through a
tube which is placed in your child’s vein, when your child is not able to eat all of his or her nutrition by
mouth.
Numeta is presented in the form of a three chamber bag in which the separate chambers contain:
a 50% glucose solution
a 5.9% paediatric amino acid solution, with electrolytes
a 12.5% lipid (fat) emulsion
Depending on your child’s needs, two or three of these solutions are mixed together in the bag before it is
given to your child.
Numeta must only be used under medical supervision.

2. What you need to know before your child is given Numeta
Your child should not be given Numeta, in the following cases:
With the glucose and amino acid/electrolyte solutions mixed together in the bag (“2 in 1”):
• If your child is allergic to egg, soya, peanuts or to any ingredient of this medicine or component of
the container (listed in section 6).
• If your child’s body has problems using building blocks of protein.
• If your child has high concentrations of any of the electrolytes included in Numeta in their blood.
• Numeta (or other calcium containing solutions) must not be given at the same time as ceftriaxone
(an antibiotic), even if separate infusion lines are used. There is a risk of particle formation in the
newborn’s bloodstream which may be fatal.
• If your child has hyperglycaemia (especially high levels of sugar in his/her blood).
With the glucose, amino acid/electrolyte and lipid solutions mixed together in the bag (“3 in 1”).
All of the above situations mentioned for the “2 in 1” plus the following:
• If your child has especially high level of fats in his/her blood.

1a

BE-30-02-363

ARTWORK DESIGN CENTRE

Version: 05

Artworker: P. Delcourt

Date: 17 MAR 2016

Draft: 3rd

Errors: Yes / No PR1:

Errors: Yes / No PR2:

Sign:

Sign:

Date:

Date:

Comments:

EMEA ARTWORK DESIGN CENTRE
ARTWORK APPROVAL
3rd DRAFT
RA TO APPROVE
LAYOUT AND
FORMAT
Country

DATE
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

In all cases, the doctor will base their decision on whether your child should receive this medicine on
factors such as age, weight and clinical condition. The doctor will also consider the results of any tests
performed.

Warnings and precautions
Talk to your child’s doctor or nurse before they are given Numeta.
Allergic reactions:
The infusion must be stopped immediately if any signs or symptoms of an allergic reaction (such as
fever, sweating, shivering, headache, skin rashes, or difficulty breathing) develop. This medicinal product
contains soybean oil, which may rarely cause hypersensitivity reactions. Uncommonly, it has been
observed that some people who are allergic to peanut proteins are also allergic to soybean proteins.
Risk of particle formation with ceftriaxone (antibiotic):
A certain antibiotic named ceftriaxone must not be mixed or given simultaneously with any calcium
containing solutions (including Numeta) given to you by a drip into your vein. Your doctor knows this and
will not give you them together even via different infusion lines or different infusion sites.
Formation of small particles in blood vessels of the lungs:
Difficulty breathing could also be a sign that small particles have formed, blocking blood vessels in the
lungs (pulmonary vascular precipitates). If your child experiences any difficulty breathing, tell your child’s
doctor or nurse. They will decide of a course of action to be taken.
Infection and sepsis:
The doctor will carefully watch your child for any signs of infection. An “aseptic technique” (i.e., germ
free technique) when placing and maintaining the catheter as well as when making the nutritional
formula can reduce the risk of infection.
Occasionally, children can develop infection and sepsis (bacteria in the blood) when they have a tube in
their vein (intravenous catheter). Certain medications and illnesses can increase the risk of developing
infection or sepsis. Patients who require parenteral nutrition (giving nutrition through a tube in your
child’s vein) can be more likely to develop infection from their medical conditions.
Fat overload syndrome:
Fat overload syndrome has been reported with similar products. The reduced or limited ability of the
body to remove the fats contained in Numeta may result in a “fat overload syndrome” (see section 4 –
Possible Side Effects).
Changes in blood chemistry levels:
The doctor will check and monitor your child’s fluids, blood chemistries and other blood values during
treatment with Numeta. Occasionally refeeding someone who is severely undernourished can result in
major changes in blood chemistry levels that may need to be corrected. Extra fluid in the tissues and
swelling can also develop. It is recommended that parenteral nutrition is started slowly and carefully.
Monitoring and adjustment:
The doctor will be closely monitoring and adjusting Numeta to meet your child’s individual needs
especially if they have the following conditions:
–– severe post-traumatic conditions
–– severe diabetes mellitus
–– shock
–– heart attack
–– severe infection
–– certain types of coma
Use with caution:
Numeta should be used with caution if your child has:
–– pulmonary oedema (fluid in the lungs) or heart failure.
–– severe liver problems.
–– problems in using nutrients correctly.
–– high blood sugar.
–– kidney problems.
–– severe metabolic disorders (when the body cannot break down substances in a normal way).
–– blood clotting disorders.
Your child´s body fluid status, liver test values and/or other blood values will be closely monitored.
There is limited information on giving this medicine in preterm (premature) infants less than 28-week
gestational age.

2a

BE-30-02-363

Version:

05

Sign:

Date:

Sign:

Date:

EMEA ARTWORK DESIGN CENTRE
ARTWORK APPROVAL
3rd DRAFT
RA TO APPROVE
LAYOUT AND
FORMAT
Country

DATE
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

Other medicines and Numeta
Tell the doctor if your child is taking or using, has recently taken or used or might take or use any other
medicines.
Numeta must not be given at the same time as:
• blood through the same infusion tubing due to the risk of pseudoagglutination (red blood cells
becoming stuck together in a stack).
• ceftriaxone (an antibiotic) because of the risk of particle formation.
Coumarin and warfarin (Anticoagulants):
The doctor will carefully watch your child if they are taking coumarin or warfarin. These medicines are
anticoagulants used to prevent clotting of the blood. Olive and soybean oil have a natural content of
vitamin K1. Vitamin K1 may interfere with medicines such as coumarin and warfarin.
Laboratory tests:
The lipids contained in this emulsion may interfere with the results of certain laboratory tests. Laboratory
tests may be performed after a period of 5 to 6 hours following the use of lipids or when no additional
lipids are administered.
Interactions of Numeta with medicines that may affect potassium levels/metabolism:
Numeta contains potassium. High levels of blood potassium may cause abnormal heart rhythm. Special
care should be taken in patients taking diuretics (medicines to reduce fluid retention) or ACE inhibitors
(medicines for high blood pressure) or angiotensin II receptor antagonists (medicines for high blood
pressure) or immunosuppressants (medicines that may lower the body’s normal immune defences).
These types of medicines may increase potassium levels.

3. How Numeta is given
Your child should always be given Numeta exactly as the doctor has indicated. Check with your doctor if
you are not sure.
Age group
Numeta G13E has been designed to meet the nutritional needs of preterm newborns.
Numeta may not be appropriate for some preterm infants, as their condition may require individualised
formulations to meet their specific nutritional needs. The doctor will decide if this medicine is suitable for
your child.
Administration
This medicine is an emulsion for infusion. It is given through a plastic tube in a vein in your child’s arm or
in a large vein in your child’s chest.
The doctor may choose not to give lipids to your child. The design of the Numeta bag allows only the peel
seal between the amino acids/electrolyte and glucose chambers to be broken if necessary. The peel seal
between the amino acids and lipid chambers remains intact in this case. The content of the bag can then
be infused without lipids.
Dosage and duration of treatment
The doctor will decide the dose and for how long it will be given. The dosage depends on the nutrition
needs of your child. The dosage will be based on your child’s weight, medical condition, and on their
body’s ability to break down and use the ingredients in Numeta. Additional nutrition or proteins given
orally/enterally may also be given.

If your child is given too much Numeta
Symptoms
Too much of this medicine, or giving it too quickly may result in the following:
–– nausea (feeling sick)
–– vomiting
–– shivering
–– electrolyte disturbances (improper amounts of electrolytes in the blood)
–– signs of hypervolemia (increase of circulating blood volume, too much fluid in the blood vessels)
–– acidosis (increased acidity of the blood)
In such situations, the infusion must be stopped immediately. The doctor will decide if additional actions
are required.
To prevent these events occurring, the doctor will regularly monitor your child’s condition and test their
blood levels during treatment.

3a

BE-30-02-363

Version:

05

Sign:

Date:

Sign:

Date:

EMEA ARTWORK DESIGN CENTRE
ARTWORK APPROVAL
3rd DRAFT
RA TO APPROVE
LAYOUT AND
FORMAT
Country

DATE
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

4. Possible side effects
Like all medicines, this medicine can cause side effects, although not every child gets them.
If you notice any changes in the way your child feels during or after the treatment, tell the doctor or
nurse immediately.
The tests the doctor will perform while your child is taking the medicine should minimise the risk of side
effects.
If signs of an allergic reaction occur, the infusion shall be stopped and a doctor contacted immediately.
This can be serious and the signs may include:
–– sweating
–– shivering
–– headache
–– skin rashes
–– breathing difficulties
Other side effects that have been noticed are:
Common: may affect up to 1 in 10 people
• Low phosphate level in the blood (hypophosphataemia)
• High sugar level in the blood (hyperglycaemia)
• High calcium level in the blood (hypercalcaemia)
• High triglycerides level in the blood (hypertriglyceridaemia)
• Electrolyte disturbance (hyponatraemia)
Uncommon: may affect up to 1 in 100 people
• High lipid level in the blood (hyperlipidaemia)
• Condition where bile cannot flow from the liver to the duodenum (cholestasis). The duodenum is a
part of the intestines.
The following side effects have been reported with other parenteral nutrition products:
• The reduced or limited ability to remove the lipids contained in Numeta may result in a “fat
overload syndrome”. The following signs and symptoms of this syndrome are usually reversible
when the infusion of the lipid emulsion is stopped:
–– Sudden and abrupt worsening of the patient’s medical condition
–– High levels of fats in the blood (hyperlipidaemia)
–– Fever
–– Liver fatty infiltration (hepatomegaly)
–– Worsening liver function
–– Reduction in red blood cells which can make the skin pale and cause weakness or
breathlessness (anaemia)
–– Low white blood cell count, which can increase the risk of infection (leukopenia)
–– Low platelet count which can increase the risk of bruising and/or bleeding (thrombocytopenia)
–– Coagulation disorders which effect the ability of the blood to clot
–– Coma, requiring hospitalisation.
• Formation of small particles which may lead to blockage of blood vessels in the lungs (pulmonary
vascular precipitates) or difficulty breathing
Reporting of side effects
If your child gets any side effects talk to the doctor or nurse. This includes any possible side effects not
listed in this leaflet.
You can also report side effects directly (see details below). By reporting side effects you can help
provide more information on the safety of this medicine.
Malta:
ADR Reporting
Website: www.medicinesauthority.gov.mt/adrportal
Republic of Ireland:
HPRA Pharmacovigilance,
Earlsfort Terrace,
IRE – Dublin 2.
Tel: +353 1 6764971,
Fax: +353 1 6762517,
Website: www.hpra.ie;
E-mail: medsafety@hpra.ie
United Kingdom:
Yellow Card Scheme: www.mhra.gov.uk/yellowcard
4a

BE-30-02-363

Version:

05

Sign:

Date:

Sign:

Date:

EMEA ARTWORK DESIGN CENTRE
ARTWORK APPROVAL
3rd DRAFT
RA TO APPROVE
LAYOUT AND
FORMAT
Country

DATE
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

5. How to store Numeta
Keep this medicine out of the sight and reach of children when not being administered.
Do not use this medicine after the expiry date which is stated on the bag and the outer packaging
(MM/YYYY). The expiry date refers to the last day of that month.
Do not freeze.
Store in the overpouch.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect the environment.

Version:

05

Sign:

Date:

Sign:

Date:

6. Contents of the pack and other information

EMEA ARTWORK DESIGN CENTRE

What Numeta looks like and contents of the pack
Numeta is presented in the form of a triple-chamber bag. Each bag contains a sterile combination
of a glucose solution, an amino acid solution for children, with electrolytes, and a lipid emulsion, as
described below.
Container size

300 mL

50% glucose solution

80 mL

5.9% amino acid
solution with
electrolytes
160 mL

12.5% lipid emulsion

60 mL

Appearance before reconstitution:
• The solutions in the amino acid and glucose chambers are clear, colorless or slightly yellow
• The lipid emulsion chamber is a uniform and milky-white liquid
Appearance after reconstitution:
• “2 in 1” solution (amino acids/electrolytes and glucose) for infusion is clear, colorless or slightly
yellow
• “3 in 1” emulsion for infusion is uniform and milky-white
The three-compartment bag is a multi-layer plastic bag.
To prevent air contact, Numeta is packaged in an oxygen barrier overpouch that also contains an oxygen
absorber.
Pack sizes
300 mL bag: 10 units per cardboard box

1 bag of 300 mL
Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder
Baxter Healthcare Ltd
Caxton Way, Thetford,
Norfolk, IP24 3SE,
UNITED KINGDOM
Manufacturer
BAXTER S.A.
BOULEVARD RENE BRANQUART, 80
7860 LESSINES
BELGIUM

5a

BE-30-02-363

ARTWORK APPROVAL
3rd DRAFT
RA TO APPROVE
LAYOUT AND
FORMAT
Country

DATE
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

This medicinal product is authorised in the Member States of the EEA under the following names:
Country

Name
Numeta G 13 % E Emulsion zur Infusion

Austria
Germany
Belgium
Luxembourg
France

NUMETZAH G13%E, émulsion pour perfusion
NUMETAH G13 %E préma émulsion pour
perfusion
Numeta G13E

Denmark
Norway
Sweden
Czech Republic
Greece
Netherlands
Ireland
Malta
United Kingdom
Italy
Finland
Poland
Portugal
Spain

NUMETA G 13 % E
Numeta G13E Preterm
NUMETA G13%E emulsie voor infusie
Numeta G13%E Preterm, Emulsion for Infusion

NUMETA G13E emulsione per infusione
Numeta G13E infuusioneste, emulsio
NUMETA G 13 % E Preterm
Numeta G13%E
NUMETA G13%E, emulsión para perfusión

This leaflet was last revised 03/2016

6a

BE-30-02-363

Version:

05

Sign:

Date:

Sign:

Date:

EMEA ARTWORK DESIGN CENTRE
ARTWORK APPROVAL
3rd DRAFT
RA TO APPROVE
LAYOUT AND
FORMAT
Country

DATE
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

The following information is intended for medical or healthcare professionals
only*
*Please observe that in certain cases this product may be administered at home by parents or other
caregivers. In such cases parents/caregivers should read the following information.
No additions to the bag should be made without first checking the compatibility. Formation of particles
or breaking down of the lipid emulsion could result. This can lead to blockage of the blood vessels.
Numeta should be at room temperature before use.

Version:

Before using Numeta, the bag will be prepared as shown below.
Confirm that the bag is not damaged. Use the bag only if it is not damaged. An undamaged bag looks
like this:
• The non-permanent seals are intact. This is indicated by no mixture of any of the three chambers
• The amino acid solution and the glucose solution are clear, colorless, or slightly yellow without
visible particles
• The lipid emulsion is a uniform liquid with a milky white appearance.
Before opening the overpouch, check the color of the oxygen indicator. Compare it to the reference color
printed next to the OK symbol and depicted in the printed area of the indicator label. Do not use the
product if the color of the oxygen indicator does not correspond to the reference color printed next to
the OK symbol.
To open: Remove the
protective overpouch.
Discard the overpouch and
oxygen absorber/ indicator
sachet.

Mixing: Ensure that the product is at room temperature when breaking the non-permanent seals. Place
the bag onto a flat clean surface Do not use the bag if the contents are mixed due to accidental rupture
of compartment seals during transport.
Activation of the 3 chambers (mixing of 3 solutions by breaking two non-permanent seals)

Start rolling the bag from the
D-hanger side.

Apply pressure until peal
seals open.

Turn the bag over at least
three times to mix the content
thoroughly. The appearance
of the mixed solution should
be a milky-white emulsion.

Remove the protective cap
from the administration
site and insert the IV
administration set.
1b

Then change direction by rolling
the bag towards the D-hanger,
continue until the seal is
completely opened. Proceed the
same way to complete the opening
of the second peel seal.

BE-30-02-363

05

Sign:

Date:

Sign:

Date:

EMEA ARTWORK DESIGN CENTRE
ARTWORK APPROVAL
3rd DRAFT
RA TO APPROVE
LAYOUT AND
FORMAT
Country

DATE
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

Activating the 2 chambers (mixing of 2 solutions by breaking the non-permanent seal between
the amino acid and glucose chambers)

PRESS
Version:

PRESS

To mix only 2 solutions,
roll the bag from the top
(hanger end) corner of
the seal separating the
solutions. Apply pressure
to open the seal separating
the glucose and amino acid
compartments.

Orient the bag such that the
lipid emulsion compartment
is nearest to the operator. Roll
the bag while protecting the
lipid emulsion compartment
in the palms of the hands.

Apply pressure with one hand
and roll the bag toward the
tubes.

Turn the bag over at least
three times to mix the content
thoroughly. The appearance
of the mixed solution should
be clear, colorless or slightly
yellow.

Remove the protective cap
from the administration site
and insert the IV administration
set.

The flow rate should be increased gradually during the first hour. The administration flow rate must be
adjusted based on the following factors:
• the dose being administered
• the daily volume intake
• the duration of the infusion.
Additions:
The capacity of the bag is sufficient to enable additions such as electrolytes, trace elements, vitamins and
water for injection. Any addition (including vitamins) may be made into the reconstituted mixture (after
the non-permanent seals have been opened and after the contents of the two or three chambers have
been mixed). Vitamins may also be added into the glucose chamber before the mixture is reconstituted
(before opening the non-permanent seals and before mixing the solutions and the emulsion).
When making additions, the amount of electrolytes already present in the bag should be taken into
account to meet the clinical needs of the patient. Maximum levels of electrolytes, and commercially
available vitamins and trace elements formulations that can be added to Numeta activated 2CB and
activated 3CB admixtures are described below. The composition of vitamins and trace elements
preparations are illustrated in Section 4.2 of the SmPC.

2b

Date:

Sign:

Date:

EMEA ARTWORK DESIGN CENTRE
ARTWORK APPROVAL
3rd DRAFT
RA TO APPROVE
LAYOUT AND
FORMAT
Country

PRESS

Change direction by rolling
the bag towards the top
(hanger end). Press with the
other hand, continuing until
the seal separating the amino
acid and glucose solutions is
completely opened.

05

Sign:

BE-30-02-363

DATE
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

Additive

Maximal Further Addition Per Bag
Amino Acids and Glucose
(Activated 2 CB)

Amino Acids, Glucose, and
Lipids (Activated 3 CB)

Sodium

17.6 mmol

5.0 mmol

Potassium

17.8 mmol

4.2 mmol

Magnesium

1.3 mmol

0.0 mmol

Calcium

3.5 mmol

1.9 mmol

Phosphatea

4.0 mmol

2.5 mmol

Trace elements

2.5 mL TE1

2.5 mL TE1

Vitamins

¼ vial V1

¼ vial V1 + ¼ vial V2

Version:

a: Organic phosphate
To perform an addition:
• Aseptic conditions must be observed
• Prepare the injection site of the bag
• Puncture the injection site and inject the additives using an injection needle or a reconstitution
device
• Mix content of the bag and the additives
Preparation of the infusion:
• Aseptic conditions must be observed
• Suspend the bag
• Remove the plastic protector from the administration outlet
• Firmly insert the infusion set spike into the administration outlet
Administration of the infusion:
• For single use only
• Only administer the product after the non-permanent seals between the two or three chambers
have been opened and the contents of the two or three chambers have been mixed
• Ensure that the final activated 3CB emulsion for infusion does not show any evidence of phase
separation or the final 2CB
solution for infusion does not show any evidence of
particles
• After opening the bag, the content must be used immediately, and never stored for a subsequent
infusion
• Do not connect any partially used bag
• Do not connect in series in order to avoid the possibility of air embolism due to possible residual
gas contained in the primary bag
• Any unused product or waste material and all necessary disposable devices must be properly
discarded and not used again.
Shelf life after the Solutions are Mixed
Use the product immediately after the non-permanent seals between the two or three chambers have
been opened. Stability studies of the mixtures have been performed for 7 days between 2°C and 8°C
followed by 48 hours at 30°C.
Shelf life after Supplementation (electrolytes, trace elements, vitamins, water)
For specific admixtures physical stability of the Numeta formulation has been demonstrated for 7 days
between 2°C and 8°C followed by 48 hours at 30°C. Information on these additions specified in section
6.6 of the SmPC (summary of product characteristics).
From a microbiological point of view, the product should be used immediately. If not used immediately,
in-use storage times and conditions prior to use are the responsibility of the user and would normally
not be longer than 24 hours at 2 to 8°C, unless reconstitution /dilution /supplementation has taken place
in controlled and validated aseptic conditions
Do not use Numeta if the bag is damaged. A damaged bag looks like this:
• The non-permanent seals are broken
• Any one of the chambers contains a mixture of any of the solutions
• The amino acid solution and the glucose solution are not clear, colorless, or slightly yellow,
and/or contain visible particles
• The lipid emulsion is not a uniform liquid with a milky white appearance.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to
dispose of medicines no longer required. These measures will help to protect the environment.

3b

BE-30-02-363

05

Sign:

Date:

Sign:

Date:

EMEA ARTWORK DESIGN CENTRE
ARTWORK APPROVAL
3rd DRAFT
RA TO APPROVE
LAYOUT AND
FORMAT
Country

DATE
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

What Numeta contains
The active substances are:
Active Substance
Amino Acid Chamber
Alanine
Arginine
Aspartic acid
Cysteine
Glutamic acid
Glycine
Histidine
Isoleucine
Leucine
Lysine monohydrate
(equivalent to Lysine)
Methionine
Ornithine hydrochloride
(equivalent to Ornithine)
Phenylalanine
Proline
Serine
Taurine
Threonine
Tryptophan
Tyrosine
Valine
Potassium acetate
Calcium chloride dihydrate
Magnesium acetate tetrahydrate
Sodium glycerophosphate hydrated
Glucose Chamber
Glucose monohydrate
(equivalent to Glucose anhydrous)
Lipid Chamber
Refined olive oil (approximately 80%) +
Refined soya-bean oil (approximately 20%)

Activated 2CB
(240 mL)

Activated 3CB
(300 mL)

0.75 g
0.78 g
0.56 g
0.18 g
0.93 g
0.37 g
0.35 g
0.62 g
0.93 g
1.15 g
(1.03 g)
0.22 g
0.30 g
(0.23 g)

0.75 g
0.78 g
0.56 g
0.18 g
0.93 g
0.37 g
0.35 g
0.62 g
0.93 g
1.15 g
(1.03 g)
0.22 g
0.30 g
(0.23 g)

0.39 g
0.28 g
0.37 g
0.06 g
0.35 g
0.19 g
0.07 g
0.71 g
0.61 g
0.55 g
0.10 g
0.98 g

0.39 g
0.28 g
0.37 g
0.06 g
0.35 g
0.19 g
0.07 g
0.71 g
0.61 g
0.55 g
0.10 g
0.98 g

44.00 g
(40.00 g)

44.00 g
(40.00 g)



7.5 g

Version:

Date:

Sign:

Date:

EMEA ARTWORK DESIGN CENTRE
ARTWORK APPROVAL
3rd DRAFT
RA TO APPROVE
LAYOUT AND
FORMAT
Country

2CB = two chamber bag, 3CB = three chamber bag

4b

05

Sign:

BE-30-02-363

DATE
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

The reconstituted solution/emulsion provides the following:

Per volume unit (mL)
Nitrogen (g)
Amino acids (g)
Glucose (g)
Lipids (g)
Energy
Total calories (kcal)
Non-protein calories (kcal)
Glucose calories (kcal)
Lipid calories a (kcal)
Non-prot calories / nitrogen
(kcal/g N)
Lipid calories (% non-protein
calories)
Lipid calories (% total calories)
Electrolytes
Sodium (mmol)
Potassium (mmol)
Magnesium (mmol)
Calcium (mmol)
Phosphate b (mmol)
Acetate (mmol)
Malate (mmol)
Chloride (mmol)
pH (approx.)
Osmolarity approx. (mOsm/L)
a
b

Composition
Activated 2CB
240
100
1.4
0.59
9.4
3.9
40.0
16.7
0
0

300
1.4
9.4
40.0
7.5

198
160
160
0
113

82
67
67
0
113

273
235
160
75
165

91
78
53
25
165

N/A

N/A

32

32

N/A

N/A

28

28

6.4
6.2
0.47
3.8
3.2
7.2
3.2
9.3
5.5
1400

2.7
2.6
0.20
1.6
1.3
3.0
1.3
3.9
5.5
1400

6.6
6.2
0.47
3.8
3.8
7.2
3.2
9.3
5.5
1150

2.2
2.1
0.16
1.3
1.3
2.4
1.1
3.1
5.5
1150

Activated 3CB
100
0.47
3.1
13.3
2.5

Version:
Sign:

Date:

ARTWORK APPROVAL
3rd DRAFT
RA TO APPROVE
LAYOUT AND
FORMAT
Country

Includes calories from egg phosphatide
Includes phosphate from egg phosphatide component of the lipid emulsion
L-Malic acid a
Hydrochloric acid a
Purified egg phosphatide
Glycerol
Sodium oleate
Sodium hydroxide a
Water for injections
for pH adjustment

5b

Date:

EMEA ARTWORK DESIGN CENTRE

The other ingredients are:

a

05

Sign:

BE-30-02-363

DATE
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

Version:

05

Sign:

Date:

Sign:

Date:

EMEA ARTWORK DESIGN CENTRE
ARTWORK APPROVAL
3rd DRAFT
RA TO APPROVE
LAYOUT AND
FORMAT
Country

6b

BE-30-02-363

DATE
PLANT APPROVAL
HALLE ONLY
N/A

Name

N/A

Signature

N/A

Date

N/A

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide